Agomab Therapeutics Acquires Origo Biopharma
December 15, 2021
Agomab Therapeutics NV has completed the acquisition of Spanish biotech Origo Biopharma, integrating Origo's team and facilities in Touro and Barcelona into Agomab's organization. The deal combines Origo's organ‑restricted small‑molecule platform targeting the TGF‑β pathway with Agomab's HGF‑targeting antibody programs to broaden the combined clinical‑stage pipeline for fibrosis therapeutics.
- Buyers
- Agomab Therapeutics NV
- Targets
- Origo Biopharma
- Industry
- Biotechnology
- Location
- Spain
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Amgen Acquires Teneobio for $900M with Up to $1.6B in Milestones
July 27, 2021
Biotechnology
Amgen agreed to acquire clinical-stage biotechnology company Teneobio for $900 million in upfront cash plus potential contingent milestone payments up to $1.6 billion. The acquisition adds Teneobio's heavy-chain antibody discovery platform, bispecific/multispecific antibody technologies and a Phase 1 T-cell engager (TNB-585), strengthening Amgen's antibody research capabilities and oncology pipeline.
-
Epsilogen Acquires TigaTx to Create Pan-Isotype Cancer Antibody Company
April 7, 2025
Biotechnology
Epsilogen Ltd has completed the acquisition of Boston-based TigaTx, Inc., making TigaTx a wholly owned subsidiary. The deal combines TigaTx's engineered IgA antibody assets with Epsilogen's IgE capabilities to build a pan-isotype oncology antibody company and broaden the combined clinical-stage pipeline.
-
AbCellera Acquires TetraGenetics
September 13, 2021
Biotechnology
AbCellera Biologics Inc. acquired TetraGenetics, Inc. in an all-cash transaction to integrate TetraGenetics' recombinant transmembrane protein expression platform into AbCellera's antibody discovery technology stack. The acquisition expands AbCellera's ability to generate antibodies against difficult-to-drug ion channels, GPCRs and other transmembrane targets, and includes upfront and milestone-based payments.
-
Valerio Therapeutics Acquires Emglev Therapeutics
September 29, 2024
Biotechnology
Valerio Therapeutics S.A. completed the acquisition of Emglev Therapeutics on September 29, 2024, transferring Emglev's proprietary synthetic single-domain antibody (sdAb) platform into a newly formed Valerio subsidiary, Valour Bio. The deal was structured as a cash sale of shares combined with a contribution-in-kind (Emglev shares exchanged for Valour Bio shares), making Emglev shareholders shareholders of Valour Bio and positioning Valour Bio to advance sdAb discovery and development across oncology and inflammatory/autoimmune indications.
-
Genmab to Acquire ProfoundBio for $1.8 Billion
April 3, 2024
Biotechnology
Genmab (Nasdaq: GMAB) and ProfoundBio announced a definitive agreement for Genmab to acquire ProfoundBio in an all-cash transaction valued at $1.8 billion. The deal will expand Genmab’s mid- to late-stage oncology pipeline by adding ProfoundBio’s next-generation antibody-drug conjugate (ADC) programs, including Rina-S.
-
Gilead Sciences Acquires MiroBio
September 20, 2022
Biotechnology
Gilead Sciences completed the acquisition of U.K.-based biotechnology company MiroBio for approximately $405 million in cash. The deal gives Gilead MiroBio's discovery platform and portfolio of immune inhibitory receptor agonists, including lead investigational antibody MB272, which is in Phase 1 clinical trials.
Track M&A activity that matters to you
Get real-time deal alerts, build buyer lists with AI, and access our full acquisition database. Start your free trial today.